July 23, 2020
Digital Pathology
Explore digital pathology, and how it‘s being used for biomarker discovery particularly within immuno-oncology.
LEARN MORE
June 11, 2020
DNA Damage Response (DDR)
Explore how various cellular DNA damage response (DDR) and DNA repair pathways are targeted to develop novel anticancer ...
LEARN MORE
April 22, 2020
The Role of Proteomics in Oncology Biomarker Discovery
Explore the evolving role of proteomics in oncology biomarker discovery, specifically identifying and analyzing ...
LEARN MORE
March 6, 2020
How to Develop Predictive Cancer Biomarkers
How to develop predictive cancer biomarkers: Explore the different types and classes of cancer biomarker, and the key ...
LEARN MORE
January 22, 2020
Cancer Cell Line Authentication
Review best practices in cancer cell line authentication, including a comparison of STR and SNP assays.
LEARN MORE
November 5, 2019
Cancer Biomarkers: Improving Detection and Treatment
Explore the three main types of cancer biomarkers and their main uses in cancer diagnosis, informing prognosis, and ...
LEARN MORE
September 17, 2019
Targeting Tumor-Associated Antigens and Tumor-Specific Antigens
Learn more about targeting human tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs) in immunotherapy development, including therapeutic approaches and preclinical models for assessing TSA/TAA targeting agents.
LEARN MORE
August 20, 2019
Circulating Tumor Cells in Preclinical Mouse Models of Metastasis
Explore the utility of preclinical mouse models of metastasis to study circulating tumor cells (CTCs) and the ...
LEARN MORE
July 19, 2019
Recapitulating Clinical Metastatic Events in Preclinical Mouse Models
Explore the preclinical mouse models that best recapitulate the progression of the clinical metastatic process.
LEARN MORE
May 30, 2019
Key Differences between hPBMC and hCD34 Humanized Mouse Models
Learn more about the different human immune cell populations in PBMC and HSC-humanized mouse models, to help select the ...
LEARN MORE
March 7, 2019
Genetic Abnormality Spectrum in Hematologic Cancers
What have we learned about the genetics of hematological cancers, and how can that be modelled for research and drug discovery?
LEARN MORE
February 12, 2019
Targeting the FGF/FGFR Signaling Axis with PDX Models
Discover the complex range of FGFR family aberrations in cancer and how PDX models are a powerful tool for assessing ...
LEARN MORE
January 8, 2019
RAS: Targeting the Impossible
Explore the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical ...
LEARN MORE
December 4, 2018
Preclinical Immunotherapy Safety and Toxicity Assessment
While the overall objectives for preclinical evaluation of cancer immunotherapies are identical to other anticancer ...
LEARN MORE
November 29, 2018
Where Do Organoids Fit in Preclinical Cancer Modeling?
There’s a wide range of new preclinical cancer models being developed, each with their own strengths and best uses. ...
LEARN MORE
